



KB220Z (marketed as SynaptaGenX™) is a proprietary, patented dopamine agonist (US #6, 132, 724 US 6,955,873) that promotes healthy dopamine supporting optimal brain health.

It has been shown in numerous studies to promote dopamine sensitivity. This cutting-edge patented composition increases satisfaction from pleasurable experiences through supplying neuronutraceuticals that are beneficial for healthy brain function. These neuronutrients help promote optimal dopamine function; normalize satiety and pleasure satisfaction from normally enjoyable activities and experiences; improve energy regulation; reduce stress; promote well-being; and increase feelings of happiness. Importantly, these benefits may help promote healthy improvements in body composition and sustainable weight management.

KB220Z has been used in extensive clinical trials as well as pre-clinical animal studies. These studies, conducted by leading universities and medical schools, including the University of California, Massachusetts Institute of Technology, John Hopkins, Yale University, University of Texas, Stonybrook University, National Institute of Drug Abuse, University of Tulane, Concordia, McGill, Toronto, Chicago, Milan, Rome and the University of Colorado, are completed and ongoing. The completed data has been published in U.S. and foreign journals, including Science, Nature, Lancet, Molecular Psychiatry, Alcohol, Archives General Psychiatry, Biochemical Pharmacology, Gene therapy & Molecular Biology, Current Neuropharmacology, Theoretical Biology and Medical Modeling, Medical Hypotheses, Psychopharmacology, British Journal of Pharmacology and JAMA. There are over 27 (so far at this writing) peer reviewed published clinical trials validating the efficacy of this groundbreaking technology.

Patented KB220 and KB220Z nutraceutical 'neuroadaptagen' technology, known as SynaptaGenX™, has been shown to reduce or eliminate excessive desires for unhealthy behaviors and pleasure-inducing substances by supporting healthy cravings through the positive influence on gene expression.

Over time, KB220Z (marketed as SynaptaGenX™) can normalize receptors in your brain.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Schizophrenics should not use a dopamine agonist. If you are pregnant, nursing, or under 12 years of age, consult a physician. KEEP THIS AND ALL DIETARY SUPPLEMENTS OUT OF REACH OF CHILDREN